Rengalin oral solution 100 ml of 1 piece

Description

Composition
Active substance:
Antibodies affinity-purified towards bradykinin 0.12 g *
Antibodies affinity-purified histamine 0.12g *
Antibodies affinity purified morphine 0.12 g *
* Are introduced into a mixture of three aqueous dilutions of the active substance, diluted respectively at 10012, 10030, 10050 times.
Excipients:
Hypromellose 1.0 g, 6.0 g of maltitol, 3.0 g glycerol, 0.165 g of potassium sorbate, citric acid anhydrous 0.02 g Purified water to 100 ml.
Description:
Colorless or almost colorless clear liquid
Product form:
Oral solution.
In 100 ml glass vials of an OS or stamp a colored glass lid sealed with a control of the first opening, with a dropper of polyethylene. Each vial together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Children up to age 3 years.
Increased individual sensitivity to the drug.
Hereditary fructose intolerance (due to the presence in the composition of maltitol).
Precautions: diabetes mellitus.
Dosage
3.6 mg / ml
Indications
Acute and chronic respiratory diseases, accompanied by cough and bronchospasm. Productive and non-productive cough with influenza and SARS, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other inflammatory and infectious-allergic diseases of the upper and lower respiratory tract.
Interaction with other drugs
In the course of clinical studies have not been received interaction data Rengalin formulation with drugs used as a concomitant therapy.
Overdose
Accidental overdosing possible dyspeptic symptoms (nausea, vomiting, diarrhea) caused by members of the excipients of the drug (maltitol, glycerol).
Treatment – symptomatic.
pharmachologic effect
Pharmacological group:
Other cold preparations.
Pharmacodynamics:
It is shown experimentally that the components of the drug activity is modified ligand-receptor interaction of endogenous regulators of the corresponding receptors: morphine antibodies (drug component) modified activity of ligand-receptor interaction of endogenous regulators to opiate receptors; Antibodies to the histamine – with H1 histamine receptors; antibodies to bradykinin – bradykinin receptors; wherein the combined use of the components leads to increased antitussive effect.
Furthermore antitussive action, due to the complex preparation of its constituent components having antiinflammatory, antiedematous, antiallergic, spasmolytic (antibody to histamine, bradykinin antibodies) and analgesic effect (antibody to morphine).
Complex preparation Rengalin through modification-dependent activation of histamine H1-receptor-dependent activation of bradykinin B1 and B2 receptors selectively reduces the excitability of the cough center of the medulla oblongata, inhibits central links cough reflex. Inhibiting pain sensitivity centers in the thalamus, blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery due to the reduction of release of tissue and plasma algogenov (histamine, bradykinin, prostaglandins, etc.). In contrast to narcotic analgesics causes no respiratory depression, drug addiction, has no narcogene and soporific effect.
Facilitates manifestations of acute pharyngitis, laryngitis, and bronchitis, reducing bronchoconstriction. Relieves systemic and local symptoms of allergic reactions due to the influence on the synthesis and release of histamine and bradykinin from mast cells.
Pharmacokinetics:
Sensitivity modern physico-chemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) does not allow to evaluate the content of active components Rengalin drug in biological fluids, organs and tissues, making it impossible technically pharmacokinetics study.
Pregnancy and breast-feeding
Security applications Rengalina in pregnancy and lactation has not been studied. During pregnancy and breastfeeding period, the drug is used only if the expected benefit to the mother outweighs the potential risk to the fetus and child. Benefit / risk ratio is determined by the attending physician.
Conditions of supply of pharmacies
Without recipe.
side effects
Possible reactions of individual hypersensitivity to the drug. If these side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
In diseases involving dry (unproductive) cough, contributes to its transition into the wet (productive) cough.
If necessary, it can be combined with mucolytics.
Diabetics should be remembered that each teaspoonful (5 ml) of the preparation contains 0.3 g of maltitol, which corresponds to 0.02 bread units (BU). For maltitol metabolism need insulin, but because of the slow hydrolysis and absorption in the gastrointestinal tract of the need for insulin is low. Energy value maltitol 10 kJ or 2.4 kcal / g, which is significantly less than that of sucrose. Energy value of one teaspoon of the drug is about 5.7 kJ (1.37 kcal).
The effect on the ability to operate vehicles, machinery
It has not been studied.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children.
Do not freeze.
Dosing and Administration
Inside. At one time – 1-2 teaspoons (5-10 ml) – without meals. It is desirable to keep the solution in the mouth before swallowing the drug to the maximal effect.
Apply 1-2 teaspoons 3 times a day. Depending on the severity of the condition in the first three days of reception frequency can be increased to 4-6 times per day.
The duration of therapy depends on the severity of the disease and is determined by the attending physician.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist